Want to see SGMT full AI Analyst Report?

Sagimet Biosciences, Inc. Class A (SGMT) Price & Analysis

1,722 Followers

SGMT Stock Chart & Stats

$7.07

$0.06(0.86%)

At close: Jul 24 4:00 PM EDT

$7.07

$0.06(0.86%)

Day’s Range― - ―

52-Week Range$4.50 - $10.06

Previous CloseN/A

Volume910.94K

Average Volume (3M)1.31M

Market Cap

$444.81M

Enterprise Value$176.17M

Total Cash (Recent Filing)$104.54M

Total Debt (Recent Filing)$39.00K

Price to Earnings (P/E)―

Beta2.90

Next Earnings

Aug 19, 2026

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.35

Shares Outstanding61,184,315

10 Day Avg. Volume983,121

30 Day Avg. Volume1,309,129

Financial Highlights & Ratios

PEG Ratio-0.42

Price to Book (P/B)1.72

Price to Sales (P/S)0.00

P/FCF Ratio-4.19

Enterprise Value/Market Cap0.40

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-3.82

Forecast

1Y Price Target

$28.88

Price Target Upside308.42% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-1.2

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetVery low leverage and a sizable equity base provide durable financial flexibility for a clinical-stage biotech. This reduces near-term default risk and gives management optionality to prioritize clinical milestones and partnerships without immediate solvency pressure, supporting multi-year R&D plans.

Meaningful Capital Raise And RunwayA $164.5M net equity raise materially extends the company’s funded runway, enabling planned U.S. Phase 3 trials and follow-on programs through key readouts. This reduces near-term financing risk and allows execution of strategic development priorities without immediate dilution-driven urgency.

Clinical/regulatory Validation In AcnePartner-run Phase 3 success and an accepted NDA provide meaningful de-risking for the lead asset, creating a regulatory precedent and commercial pathway. This clinical validation strengthens the franchise DNA, supports broader dermatology positioning, and underpins long-term development optionality across indications.

Bears Say

Negative Free Cash FlowPersistently negative free cash flow indicates structural cash burn inherent to late-stage development. Even with recent financing, the company will remain dependent on external capital until commercialization or sustainable revenue, which can constrain strategic choices and introduce recurring financing risk.

Minimal Revenue; Large Operating LossesVery limited revenue and sizable operating losses reflect that value creation is contingent on future approvals or partner milestones. This persistent unprofitability pressures returns on equity and means shareholder value is highly sensitive to binary clinical and regulatory outcomes over the medium term.

Pipeline And Funding Concentration RiskCommercial and development progress is concentrated in denifanstat and reliant on partner-generated data and external funding for other programs. This creates single-asset and sponsor-dependence risk: adverse trial or funding outcomes could disproportionately harm the company’s clinical and financial trajectory.

Sagimet Biosciences, Inc. Class A News

Sagimet, PNC, United Rentals, Rani, Southern Copper Insider Shake-Up

Insiders have been trading these 5 stocks: (($SGMT)), (($PNC)), (($URI)), (($RANI)) and (($SCCO)). Here is a breakdown of...

5d ago

PNC

URI

Sagimet updates acne pipeline and funding strategy

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) just unveiled an announcement. On July 20, 2026, Sagimet Biosciences...

10d ago

SGMT

Sagimet Therapeutics: Buy Rating Affirmed as Clinically De‑Risked FASN Franchise Advances; Price Target Raised to $31

Sagimet Biosciences, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

29d ago

SGMT

Sagimet Biosciences joins Russell 3000, Russell 2000 Indexes

Sagimet Biosciences (SGMT) announced that the company has been added to the broad-market Russell 3000 Index and small-cap...

1M ago

SGMT

Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged

Analyst Yun Zhong from Wedbush maintained a Buy rating on Sagimet Biosciences, Inc. Class A and keeping the...

1M ago

SGMT

Sagimet Biosciences Announces Board Changes and Director Elections

The latest update is out from Sagimet Biosciences, Inc. Class A ( ($SGMT) ). On June 12, 2026,...

2M ago

SGMT

Sagimet Biosciences Grants New Performance-Based Executive Equity Awards

An announcement from Sagimet Biosciences, Inc. Class A ( ($SGMT) ) is now available. On May 28, 2026,...

2M ago

SGMT

Sagimet Biosciences price target lowered to $12 from $35 at Citizens

Citizens lowered the firm’s price target on Sagimet Biosciences (SGMT) to $12 from $35 and keeps an Outperform...

2M ago

SGMT

Options Volatility and Implied Earnings Moves This Week, May 18 – May 22, 2026

This week, several major companies will be reporting earnings. Among them are Nvidia (NVDA), Nio (NIO), Walmart (WMT),...

2M ago

SGMT Upcoming Earnings Report: What to Expect?

Sagimet Biosciences, Inc. Class A (SGMT) is scheduled to report 1st quarter earnings on 05/20/2026, before the market...

2M ago

SGMT

Sagimet Biosciences price target lowered to $28 from $37 at Clear Street

Clear Street lowered the firm’s price target on Sagimet Biosciences (SGMT) to $28 from $37 and keeps a...

3M ago

SGMT

Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Sagimet Biosciences, Inc. Class A. The associated...

3M ago

SGMT

Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)

“Our recent strategic decision to focus on dermatology marks a turning point for Sagimet, and we are excited...

3M ago

SGMT

Sagimet Biosciences price target raised to $49 from $28 at Canaccord

Canaccord raised the firm’s price target on Sagimet Biosciences (SGMT) to $49 from $28 and keeps a Buy...

3M ago

SGMT

SGMT FAQ

What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?

Sagimet Biosciences, Inc. Class A lowest stock price was $4.50 and its highest was $10.06 in the past 12 months.

What is Sagimet Biosciences, Inc. Class A’s market cap?

Sagimet Biosciences, Inc. Class A’s market cap is $444.81M.

When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?

Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Aug 19, 2026 which is in 19 days.

How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?

Sagimet Biosciences, Inc. Class A released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.371 by $0.041.

Is Sagimet Biosciences, Inc. Class A overvalued?

According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sagimet Biosciences, Inc. Class A pay dividends?

Sagimet Biosciences, Inc. Class A does not currently pay dividends.

What is Sagimet Biosciences, Inc. Class A’s EPS estimate?

Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.25.

How many shares outstanding does Sagimet Biosciences, Inc. Class A have?

Sagimet Biosciences, Inc. Class A has 61,184,315 shares outstanding.

What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?

Sagimet Biosciences, Inc. Class A reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.371. Following the earnings report the stock price went down -0.52%.

Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?

Currently, no hedge funds are holding shares in SGMT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sagimet Biosciences, Inc. Class A Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-26.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sagimet Biosciences, Inc. Class A

Sagimet Biosciences, Inc. (SGMT) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics that target fatty acid synthase (FASN) to treat metabolic and liver-related diseases. The company’s development efforts have centered on drug candidates for conditions such as metabolic dysfunction–associated steatohepatitis (MASH/NASH), leveraging its FASN-inhibition approach to address dysregulated lipid metabolism.

Sagimet Biosciences, Inc. Class A (SGMT) Earnings & Revenues

Historic Earnings Reports

SGMT Stock 12 Month Forecast

Average Price Target

$28.88

▲(308.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","27":"$27","50":"$50","15.5":"$15.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,15.5,27,38.5,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.46,10.655384615384616,13.850769230769231,17.046153846153846,20.24153846153846,23.436923076923076,26.632307692307695,29.82769230769231,33.02307692307692,36.21846153846154,39.41384615384615,42.60923076923077,45.80461538461539,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.46,9.107307692307693,10.754615384615384,12.401923076923076,14.049230769230768,15.69653846153846,17.343846153846155,18.991153846153846,20.638461538461538,22.28576923076923,23.93307692307692,25.580384615384613,27.22769230769231,{"y":28.875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.46,7.809230769230769,8.158461538461538,8.507692307692308,8.856923076923078,9.206153846153846,9.555384615384614,9.904615384615385,10.253846153846155,10.603076923076923,10.952307692307691,11.301538461538462,11.650769230769232,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.72,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 81, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 122, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 111, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.46,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 66, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >